Recursion Shares Fall as Investors Await Financial Results

Recursion Pharmaceuticals closed at $3.70 in the latest trading session, down 1.2% from the previous day. The decline was steeper than the S&P 500’s 0.77% loss, the Dow’s 0.67% drop and the Nasdaq’s 0.92% fall.

The biotechnology company’s shares gained 11.98% over the previous month. That outpaced the Medical sector, which fell 3.65%, and the S&P 500, which rose 0.96%.

Ahead of Recursion’s upcoming financial results, Zacks consensus estimates call for earnings per share of -$0.24 and revenue of $8.42 million. The projected earnings figure is up 33.33% from the prior-year quarter, while estimated revenue growth is 62.57%.

For the full year, Zacks estimates earnings of -$0.94 per share and revenue of $40.32 million. Those figures represent changes of 34.72% higher for earnings and 46.01% lower for revenue compared with the preceding year.

The consensus estimate for quarterly earnings per share has fallen 2.82% over the past month, according to Zacks.